Previous 10 | Next 10 |
BioMarin Pharmaceutical (BMRN) presents updated data on its investigational treatment, vosoritide, in children with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short stature in humans.The Phase 2 extension study showed that improvement in growth velo...
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice Normal Progression of Bone Age with Chronological Age...
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques...
A rectangle pattern has formed in the chart of BioMarin Pharmaceutical Inc. (BMRN). When this pattern is broken, a breakout or breakdown could soon occur. Read more to learn how to take advantage of this setup. Shares of BioMarin Pharmaceutical Inc. ( BMRN ) have been trending sideways an...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The energy and shipping markets take center stage next week as the drama in the Suez Canal continues to play out and OPE...
BioMarin Pharmaceutical (BMRN) has announced new Phase 3 data from an open-label long-term extension study to support the lasting treatment benefit of vosoritide in children with achondroplasia.The presentation at ENDO21, the Endocrine Society's Annual Meeting showed that the invest...
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide Height Gain is Maintained in 2nd Year of Treatment PR Newswire SAN...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). On August 19, 2020, the Company disclos...
BMRN's core business value is around $78 per share. Even with conservative assumptions, ValRox represents a significant commercial opportunity. Vosoritide's prospects are also undervalued by the market. According to my DCF model, the target price for BMRN shares is $115. ...
BioMarin Pharmaceutical (BMRN) announces that the U.S. FDA granted Regenerative Medicine Advanced Therapy ((RMAT)) designation to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.RMAT is an expedited program intended to facilitat...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...